# Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)

> **NCT03401320** · PHASE1 · COMPLETED · sponsor: **Rovi Pharmaceuticals Laboratories** · enrollment: 53 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Letrozole ISM

## Key facts

- **NCT ID:** NCT03401320
- **Lead sponsor:** Rovi Pharmaceuticals Laboratories
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-06
- **Primary completion:** 2024-05-17
- **Final completion:** 2024-05-17
- **Target enrollment:** 53 (ACTUAL)
- **Last updated:** 2024-12-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03401320

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03401320, "Evaluation of IM Letrozole ISM® Pharmacokinetics, Safety, and Tolerability in Healthy Post-menopausal Women (LISA-1)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03401320. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*